Glaukos (GKOS) Q4 2025 earnings review
iDose TR Hyper-Growth Overshadows Massive GAAP Write-Down
Glaukos delivered a thunderous revenue beat with Q4 sales of $143.1M (+36% YoY), continuing a streak of accelerating growth driven by the U.S. Glaucoma franchise (+53%). However, the bottom line was messy: a $112.9M impairment charge related to the Avedro acquisition crushed GAAP EPS to $(2.32). Looking past the accounting noise, execution is flawless: Non-GAAP Gross Margins expanded to 85%, and iDose TR adoption is scaling faster than initially projected (~$45M in Q4). 2026 guidance suggests a normalization of growth to ~20%, but the trajectory remains highly bullish.
🐂 Bull Case
The U.S. Glaucoma segment grew 53% YoY, fueled by ~$45M in iDose TR sales (up from $40M in Q3). The product has fundamentally changed the company's growth profile, turning a mid-teens grower into a 30%+ grower.
Non-GAAP Gross Margin hit 85% in Q4, up 280 bps YoY. As high-margin iDose revenue becomes a larger mix percentage, the company is building significant earnings power despite current reinvestment phases.
🐻 Bear Case
SG&A expenses surged 37% YoY to $94.7M, outpacing even the rapid revenue growth. The company is burning cash to fuel the launch, with Non-GAAP Operating Loss remaining stubborn at $(16.4)M despite record sales.
The $112.9M impairment charge signals the end of the Photrexa era. While Epioxa is superior, the transition involves switching standard-of-care, which carries execution risk and potential revenue air pockets in early 2026.
⚖️ Verdict: 🟢🟢
Strong Bullish. The revenue momentum is undeniable. The GAAP impairment is a non-cash accounting cleanup of old tech (Avedro) to make way for new tech (Epioxa). With iDose annualizing at ~$180M run-rate within its first full year, the thesis is fully validated.
Key Themes
U.S. Glaucoma Franchise Explosion
The U.S. Glaucoma business has gone parabolic, growing 53% YoY to $86.4M. This is entirely driven by iDose TR, which generated ~$45M in the quarter. The adoption curve is steepening as reimbursement stabilizes across MACs.
Massive Impairment Charge
Glaukos recorded a $112.9M impairment charge related to the Avedro acquisition. This effectively writes down the value of the legacy Photrexa asset as the company pivots to Epioxa. While non-cash, it highlights that the previous acquisition did not yield the long-term longevity originally hoped for, necessitating a platform switch.
Gross Margin Expansion
Non-GAAP gross margin expanded to roughly 85% from 82% a year ago. This confirms that iDose TR is highly accretive to the margin structure. This leverage is currently masked by heavy SG&A investment but provides a clear path to profitability once OpEx scales normalize.
Operating Leverage Lag
Despite a 36% surge in revenue, Non-GAAP SG&A grew 37% ($94.5M) and R&D grew 20%. The company is essentially spending every incremental dollar of gross profit on commercial expansion. Investors looking for near-term breakeven will be disappointed as the 'investment phase' extends.
Immunity to Tariff Headwinds
Management explicitly addressed the tariff environment, stating they manufacture and source primarily within the U.S., expecting 'minimal direct exposure.' In a medtech sector currently rattled by trade war fears, this domestic supply chain is a distinct premium factor.
Corneal Health Stagnation
While U.S. Glaucoma grew 53%, Corneal Health grew only 12% ($24.0M). This segment is in a holding pattern awaiting the Epioxa launch. With the $112M write-down of the legacy asset, there is significant pressure on Epioxa to reignite growth in this segment in 2026.
Other KPIs
Stable. Up slightly from $277.5M in Q3. The company has zero debt. Cash burn has effectively ceased on a net basis, thanks partly to stock-based comp add-backs and working capital management, despite the reported GAAP losses.
Steady growth of +18% reported (+13% constant currency). While overshadowed by the U.S. iDose launch, the international business provides a durable double-digit growth baseline.
Guidance
Decelerating. The midpoint ($610M) implies ~20% YoY growth, down from the blistering 32% pace of 2025. This reflects the law of large numbers and likely some conservatism around the Epioxa transition, but remains a top-tier growth rate for the sector.
Key Questions
Epioxa Launch Curve
With the massive impairment of Photrexa, you are betting the house on Epioxa. Can you quantify the expected 'disruption' in H1 2026 as accounts switch over, and do you expect Corneal Health to return to 20%+ growth in FY26?
Spending Discipline
SG&A grew faster than revenue in Q4 (37% vs 36%). When can investors expect the 'jaws' to open where revenue growth significantly outpaces OpEx growth to deliver operating profit?
iDose Penetration Caps
U.S. Glaucoma growth is explosive. Are you approaching any capacity constraints on surgeon training or production that might bottle-neck growth in 2026?